Literature DB >> 11164380

In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor.

S Fischer1, D Renz, W Schaper, G F Karliczek.   

Abstract

Clinically, dexamethasone is known to reduce cerebral edema. To further investigate the mechanism of this neuroprotection, an in vitro model of brain-derived microvessel endothelial cells (BME cells) was used to investigate the effect of dexamethasone on hypoxia-induced hyperpermeability. Furthermore, the expression of vascular endothelial growth factor (VEGF), which is known to be the mediator of hypoxia-induced hyperpermeability, was evaluated. Dexamethasone (40 microg/ml=100 microM) decreased hypoxia-induced permeability and VEGF expression significantly during time periods of more than 3 h. The time dependence of the dexamethasone effect correlated with a changed mechanism by which hypoxia induced VEGF expression. This was deduced because hypoxia-induced hyperpermeability and VEGF mRNA level were decreased in the presence of an antisense oligonucleotide coding for a region which binds a mRNA stabilizing protein, but only up to 3 h of hypoxia. Furthermore, during this time period the half-life of VEGF mRNA was increased. Results suggest that dexamethasone only decreases transcriptional-induced VEGF expression and that this may be related to the efficacy of dexamethasone to treat brain edema.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164380     DOI: 10.1016/s0014-2999(00)00915-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study.

Authors:  Colleen Glyde Julian; Andrew W Subudhi; Megan J Wilson; Andrew C Dimmen; Travis Pecha; Robert C Roach
Journal:  J Appl Physiol (1985)       Date:  2011-06-02

2.  Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Authors:  Sung-Suk Chae; Walid S Kamoun; Christian T Farrar; Nathaniel D Kirkpatrick; Elisabeth Niemeyer; Annemarie M A de Graaf; A Gregory Sorensen; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 3.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 4.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

5.  Trans-Tenon's retrobulbar injection of triamcinolone acetonide for diffuse diabetic macular edema.

Authors:  Mitsumasa Wada; Nahoko Ogata; Keizo Minamino; Masataka Koriyama; Akiko Higuchi; Miyo Matsumura
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

6.  Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator.

Authors:  Haiyu Guo; Young-Hwan Ban; Yeseul Cha; Eun Suk An; Jieun Choi; Da Woom Seo; Dongsun Park; Ehn-Kyoung Choi; Yun-Bae Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

7.  Dexamethasone blocks the systemic inflammation of alveolar hypoxia at several sites in the inflammatory cascade.

Authors:  Jie Chao; Zachary Viets; Paula Donham; John G Wood; Norberto C Gonzalez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-18       Impact factor: 4.733

8.  Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema.

Authors:  Mücella Arıkan Yorgun; Yasin Toklu; Melek Mutlu
Journal:  Int Ophthalmol       Date:  2016-05-12       Impact factor: 2.031

9.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Steroid effects on osteogenesis through mesenchymal cell gene expression.

Authors:  Xudong Li; Li Jin; Quanjun Cui; Gwo-Jaw Wang; Gary Balian
Journal:  Osteoporos Int       Date:  2004-06-15       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.